Skip to Main Content

Otsuka Pharmaceutical has started selling Rejoyn, its Food and Drug Administration cleared prescription app that treats the symptoms of major depressive disorder. And it’s hitting the market at a low price that Otsuka hopes will entice many people to give it a try.

Otsuka will make the 6-week treatment available to patients through a prescription from their existing provider or through the treatment’s website where they can connect with a clinician from Wheel Health who can prescribe it. Rejoyn will cost an introductory price of $50 out-of-pocket plus the cost of the optional Wheel consultation. Though no insurers have agreed to cover Rejoyn yet, Otsuka says it will charge them $200.

advertisement

For context, before it went bankrupt, Pear Therapeutics had charged upwards of $1,000 for its prescription cognitive behavioral therapy apps.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.